The aim of this study is to evaluate how critical patient involvement is in pharmacist-led clinical medication reviews and in identifying the most significant clinical drug-related problems (DRPs).
Introduction
A substantial proportion (27-73%) of drug-related problems (DRPs) identified in medication reviews is discovered by interviewing the patient [1] . Furthermore, a high proportion of these DRPs has also been found to be clinically significant [1] [2] [3] . However, there is little research evaluating how important patient involvement is in identifying most significant clinical DRPs in clinical medication reviews (CMRs).
Inappropriate drug use and prescribing have been shown to be associated with mortality, morbidity, hospitalisation and healthcare costs [4] [5] [6] [7] . Collaborative pharmacist-led medication review procedures have been developed in many countries to improve the quality, safety and appropriate use of medicines through detecting DRPs and recommending interventions [8] [9] [10] [11] [12] [13] . While it has not been shown that CMRs would prevent death and hospital admissions [14] [15] [16] , they might reduce emergency department visits in hospitalised patients [14] . There is also evidence that the number of DRPs per patient can be decreased and medication knowledge and adherence of patients can be improved through CMRs, and hence it is possible to improve the quality of pharmacotherapy especially in older people [2, 3, 8, 15, [17] [18] [19] .
CMRs should always include access to patient information, such as clinical conditions and laboratory test results, and patient involvement (e.g. home-based interview) [11, 20, 21] . However, patient interviews are time consuming and they increase the costs of the medication review process [1] [2] [3] . Consequently, the involvement of patients in CMRs has been questioned [1] . Is there a need to interview the patient, or can medication reviews be conducted reliably without patient involvement? The aim of this study was to examine how critical patient involvement is in pharmacist-led CMRs and in identifying the most significant clinical DRPs.
Methods

Context of the study and study design
This study was a part of a longitudinal randomised controlled trial (Care Plan 2100 research project) in primary care setting in Tornio, Finland, with 22 000 inhabitants. Consenting patients were enrolled to the study between October 2014 and May 2016. The research project was conducted in collaboration with Tornio Health Centre (GPs, nurses and a pharmacist; setting and intervention providers), Alatornio Community Pharmacy (a pharmacist; intervention provider) and Faculty of Pharmacy, University of Helsinki (three pharmacists; intervention providers and researchers). The study reported here focusses on the baseline of the Care Plan 2100 research project (Figure 1 ). The study protocol was approved by the regional North Ostrobothnia Hospital District ethics committee (32/2014).
Identifying and recruiting patients
All outpatients aged ≥75 years were identified with the help of the Tornio health centre patient data management system databases (Pegasos, CGI) and listed to Microsoft Excel (2013; Figure 2 , Phase 1). Patients were approached and recruited in random in several rounds. The number of patients needed for each recruitment round was determined and candidates for recruitment were selected in random using Microsoft Excel. Inclusion criteria were: age ≥75 years; home-dwelling; and at least seven prescribed medicines, dietary supplements or lotions/creams. Exclusion criteria were: living in a care home; having been admitted to a hospital ward; having been appointed a guardian of interests; not a resident of Finland (Tornio is on the border between Finland and Sweden); not a resident in Tornio; or a geriatrician had completed a clinical medication review in the last 2 years. If the patients met the inclusion criteria at the time of the recruitment, they were eligible to participate. The process was repeated until the number of patients needed for the randomized-control trial (n = 300) was completed. Participants for the Care Plan 2100 research project were aged and multimorbid (seven or more drugs presumed to indicate multimorbidity) yet homedwelling so that the effects of supporting their health could potentially lead to differences between intervention and control groups (n = 150 in both), for example, in the use of health care services.
Patient recruitment information included a cover letter, information on the study, informed consent form and a prepaid self-addressed return envelope. Patients who returned the signed consent form were divided in random into two groups by an envelope method, in which the uppermost remaining envelope including the designation of the group was picked from a box, opened and the patient was placed in either the intervention or control group.
Medication review process (intervention)
Medication reviews were completed following the national collaborative CMR procedure [11] . The intervention comprised a pharmacist-led clinical medication review with at-home patient interview and an interprofessional (a GP, a pharmacist and a nurse) case conference meeting ( Figure 2 , Phases 2 and 3). The CMRs were performed by four pharmacists (two with BSc, one with MSc, one with PhD) all accredited to complete medication reviews.
A structured interview form was used to lead the informal interview and data collection [11] . At the beginning of the interview the pharmacist compared the health centre medication list to the patient's actual use of prescription and over-the-counter (OTC) drugs and dietary supplements. The interview covered themes of background details (e.g. dosing, and drug allergies), therapy control, experienced DRPs, potential adverse drug reactions and health history (e.g. smoking, alcohol use, exercise and nutrition). Furthermore, the pharmacists were to recognise any drug administration problems such as inappropriate timing of administration, poor storage conditions and expired medications, and also discuss the patient's experiences and alleviate any concerns with drugs they might have had. During the interviews, patients were encouraged to mention any health-and medicine-related issues that were important to them and any health-related goals towards which they wanted to work. The pharmacist documented the interview using the form and wrote notes about any other drug-related issues and possible DRPs that were discussed in addition to the topics in interview form. Depending on their preference, the pharmacists could use the health centre medication lists and clinical records before or during the patient interview. However, after the interview, the interviewing or another pharmacist performed the actual CMR (based on the evaluation of the interview notes, laboratory results, medication lists and other clinical records). The reviewing pharmacist wrote a CMR report that included patient characteristics, DRPs, other findings and recommendations to be presented at an interprofessional case conference.
Additionally, a nurse visited and interviewed the patients about health-related issues. At the start, there were two separate visits, but to save time and resources, at most patient interviews, both a pharmacist and the nurse were present at the Figure 1 Patient flow and the clinical medication reviews included in the analysis same time. The nurse composed a health report based on the interview and the primary care clinical records to also be presented at the interprofessional case conference. At the interprofessional case conference, a GP, the nurse and a pharmacist reviewed the CMR report and the health report, discussed the DRPs and health-related issues, made decisions based on the pharmacist's and nurse's recommendations and created a care plan for each patient.
Outcomes measures
At the end of each interprofessional case conference the pharmacist, the nurse and the GP evaluated individually the clinical significance of the identified DRPs ( Figure 2 , Phase 3). A five-point Likert scale was used (1 = no significance, 2 = slightly significant, 3 = moderately significant, 4 = significant, 5 = very significant), and the most significant clinical DRPs were identified by calculating the sum of the clinical significance ratings for each DRP ( Figure 2 , Phase 4). DRPs with a significance rating sum between 12 and 15 were viewed as highly significant since the mean value of those was four (significant) or more. These problems were then classified as unrelated to medicines/technical problems or clinical DRPs, the latter of which were grouped into two categories: identified through patient interview; and identified through patient details in patient data system. The clinical DRPs were included in the analysis.
The clinical DRPs were first classified using the PCNE Classification v 7.0 (Pharmaceutical Care Network Europe 2016) [22] . However, the classification criteria were modified so that DRPs identified during patient interview could be classified in detail. The researcher (H. Kari) performed inductive content analysis of the CMR case reports and classified the DRPs [23] .
Two researchers (H. Kari, H. Kortejärvi) evaluated independently if the most significant clinical DRPs identified during the patient interview could also have been identified by reviewing the health centre medication list only, or by reviewing the medication list and certain patient details (age, sex, medical conditions, laboratory results, drug allergies and contraindications; Figure 2 , Phase 5). After the independent review, the researchers had a consensus discussion.
Statistical analysis
The characteristics of the participants (age, sex, glomerular filtration rate, smoking, diseases, medications) are shown as frequencies for categorical variables and means with standard deviations and ranges for continuous variables. All analyses were performed using SPSS software (version 23.0) and Microsoft Excel (2016). The quality of the data entries was checked before starting the analyses.
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Results
Patient flow and characteristics
A total of 2324 patients were identified in the patient data management system and 831 recruitment letters were sent to eligible patients who met the inclusion criteria ( Figure 1 ). Of these, 323 patients (38.9%) returned the recruitment letter, and of these, 174 patients were randomized to the intervention group. Eventually, 161 patients' clinical medication reviews were included into this study. Two patients had fewer than seven prescribed drugs in the patient data management system when the updated medication list for the interview was printed. However, these two had had seven prescribed drugs at the time of the recruitment and, thus, were included in this study.
The mean age of the patients (n = 161) was 81 years and 62% were women ( Table 1 ). The prevalence of cardiovascular system diseases was 91% and endocrine system diseases 39%.
One fifth of the patients had or had had a malignant disease. According to the patient data system patients used on average 12 prescribed drugs/dietary supplements/lotions, of which 10 were prescribed to be taken regularly and two taken as required. However, during the interviews, patients reported that medication lists were not up to date and there were on average three drugs that patients did not use and one regular drug that was not listed. In addition, there was also on average one drug that patients used with deviating dosages compared with those on medication lists.
Types of the most significant clinical DRPs
Altogether, 167 (28.3%) of 590 clinical DRPs received a significance rating sum ≥12 that was significant or highly significant (Figure 3) for the 161 patients. Two-thirds (66.5%, n = 111) of the most significant clinical DRPs were identified through the patient interviews, and 33.5% (n = 56) were identified through patient information in patient data Table 1 Patient characteristics in this study derived from health centre patient registers (n = 161) Active smokers a , b , n (%) n = 141 10 (7.1) 6 (11.3) n = 53 4 (4.5) n = 88
Most common diagnosed diseases, n (%) Cardiovascular system (hypertension, heart failure, coronary heart disease, arrhythmia, hypercholesterolaemia) Regular drugs 9.7 ± 3.8 (3-24) 9.7 ± 3.9 (4-24) 9.7 ± 3. SD, standard deviation; COPD, chronic obstructive pulmonary disease system. Eleven main types of DRPs were identified using the inductive content analysis. The most frequently identified types of the most significant clinical DRPs through the patient interviews were ( Table 2 , n = 111): poor therapy control (28/111, 25%); nonoptimal drug (24/111, 22%); intentional nonadherence (13/111, 12%); additional drug needed (12/111, 11%); unintentional nonadherence (9/111, 8%); and use of OTC medicines or dietary supplements (7/111, 6%). The most significant clinical DRPs identified through patient information in the patient data system were: nonoptimal drug (20/56, 36%); need for monitoring (13/56, 23%); indication for use of medication is unclear (10/56, 18%); additional drug needed (9/56, 16%); poor therapy control (3/56, 5%); and intentional nonadherence (1/56, 2%). DRPs identified during the patient interviews were included in the further analysis.
Patient involvement in identifying the most significant clinical DRPs
After the independent evaluation of the 111 DRPs identified during the patient interviews, the two researchers had reached agreement on the 98 DRPs whether they could or could not have been identified without the interview. The researchers discussed the remaining 13 DRPs and reached consensus. They agreed that only 6% (n = 7) of the most significant clinical DRPs identified during the patient interview (n = 111) could also have been identified by using the medication list only and 16% (n = 18) could also have been identified by using the medication list and certain patient details (Table 2) . Hence, 84% (n = 93) of the most significant clinical DRPs identified in patient interview could be identified through patient involvement only. Patient involvement was critical when identifying most significant clinical DRPs related to additional drug needed, unintentional nonadherence, use of OTC medicines or dietary supplements, contradictions in counselling, and medication costs. Only some nonoptimal drug DRPs (7/24) could have been identified by using the medication list only. By combining the information on the medication lists and the patient details, few poor therapy control (4/28), intentional nonadherence (3/13), need for monitoring (2/3), indication for use of medication is unclear (1/3), and other (1/4) DRPs could have been identified without patient involvement.
Patients showed concern or even fear related to medicines use in 13 out of 111 DRPs (12%) identified through patient interviews. This was related to poor therapy control (n = 7), intentional nonadherence (n = 3), nonoptimal drug (n = 1), medication costs (n = 1) and others (n = 1).
Discussion
Main findings
The results of this study endorse that patient involvement is an integral part of clinical medication reviews. Many clinical Figure 3 Flow chart of all drug-related problems (DRPs; n = 933) identified by the pharmacists, the clinical DRPs with the clinical significance rating (n = 590) and the most significant clinical DRPs with the clinical significance rating sum ≥12 (n = 167) Table 2 The most significant clinical drug-related problems (DRPs) identified through patient interview (n = 111) divided into 11 groups DRPs are identified through patient interviews, which is comparable to findings of previous studies [1] [2] [3] . Kwint et al. also found that DRPs assigned a high priority were more likely to be identified during patient interviews than from medication and clinical records in primary care [3] . Furthermore, our study showed that there are types of DRPs that cannot be identified through reviewing medication list, or medication list and patient details. Patient interviews are essential when identifying DRPs, for example, related to poorly controlled therapy, possible adverse drug reaction, unintentional use of the drug for wrong purpose, inappropriate use of OTC medicines or dietary supplements, or contradictions in counselling. Additionally, medication lists and patient details cannot generally be used to discover if the patient intentionally does not take the prescribed medicine or does not follow the instructions given.
Role of the health care professionals
The majority of the most significant clinical DRPs that could be identified only through patient interviews were related to poorly controlled therapy. Evidently, drug therapies are started, but effectiveness of the therapies, possible adverse drug reactions, proper drug use and patients' compliance to drugs are not routinely controlled or not even discussed with the patients. For example, our findings related to nonadherence of use of cholesterol medicines are similar to recent results of Silvennoinen et al., which showed that most of the nonpersistent statin users had discontinued the medication without discussing it with a physician [24] , and to findings of Kwint et al. [3] and Krska et al. [19] that compliance issues and adverse effects were frequently identified through patient interviews. Along with patient involvement, it is important to clarify health care professionals' roles and responsibilities in monitoring and controlling drug use to Indication for use of medication is unclear
Indication for use of medication is unclear (n = 2): buprenorphine for restless legs syndrome, calcium/vitamin D for hypoparathyroidism. ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; NSAIDs, nonsteroidal anti-inflammatory drugs; INR, international normalized ratio ensure effective drug therapy and to avoid, reveal and solve DRPs in primary care settings. Interprofessional team work, pharmacist-led clinical medication reviews and patientcentred care-coordination including patient participation should be used to gain information about relevant DRPs and to improve drug therapy control. This could result in better drug therapy outcomes, fewer DRPs and better quality of life of the patient. However, it is also important to study costeffectiveness of this kind of care as resources in health care are scarce and must be allocated efficiently. In Finland, prescriptions can be (since 1 January 2017) valid for 2 years, after which they can be renewed, which should result in community pharmacists playing even more integral role in identifying and solving DRPs. Partnerships with patients might increase at community pharmacies. Indeed, a great proportion of the most significant clinical DRPs identified through patient interviews as a part of CMRs in our study, could have also been identified at community pharmacies by medication counselling and interviewing the patient, or, obviously, during GP appointments. These DRPs include, for example, poor therapy control and nonoptimal drugs for the patient that were the most common clinical DRPs identified through patient interviews in our study.
Need for monitoring
Patients' concerns or even fear related to medicines use was present in 12% of the DRPs identified through patient involvement. Face-to-face contact with patients and open discussions are essential in developing a trusting relationship with health care professionals, which is the basis for counselling and revealing possible concerns and fears [11] . Furthermore, all health care professionals should attend to giving clear and nonconflicting drug information to patient throughout the health care system.
Patient involvement and empowerment
Our study showed that CMR including patient interview is a tool for revealing DRPs, for example related to poor therapy control and nonoptimal drugs. Moreover, patient interview and involvement could also be a great opportunity for pharmacists to empower patients in appropriate drug use and self-management, and furthermore to identify possible drug-related concerns or fears. It has been widely suggested that the focus on chronic and multimorbid patients' care should progress from monitoring and supporting medication-taking and health-related behaviour (adherence) to concordance and further to patient empowerment [25] [26] [27] [28] . In health promotion, empowerment is a process through which people gain greater control over decisions and actions affecting their health [29] . There is, for example, evidence that pharmacists' support and reinforcement based on empowerment contribute to the patients' sustained motivation to diabetes care [30] .
Medication nonadherence among patients with chronic medical conditions is common [31] [32] [33] . However, those DRPs classified, for example, to intentional or unintentional nonadherence, patients receiving conflicting counselling, or use of OTC medicines or dietary supplements in our study could also be consequence of limited health literacy skills that are common in older people [34] [35] [36] . Health literacy represents cognitive and psychosocial skills, such as memory, reasoning, verbal ability, reading, numeracy, critical thinking and self-efficacy, which determine the motivation and ability of individuals to gain access to, understand and use information in ways which promote and maintain good health [29, 37] . Patients with low health literacy skills could be those who especially benefit of the pharmacists' home visits and CMRs. Active listening, asking appropriate questions, tailored patient information, and use of several channels of information should be used to support these patients' medication adherence and health empowerment. Nevertheless, it must be noticed that not all people and different disease groups of patients need same medicines information and want to be that much involved in health-related decision making [38] . To conclude, patients should be viewed as individuals when providing medicines-and health-related information and empowerment. To improve patientcentredness and identifying of DPRs, clinical interviewing techniques of pharmacists, GPs and other health care professionals, and patient empowerment skills should be improved, and they should be encouraged to identify patients with limited health literacy skills [39, 40] . Patients might also benefit having their own trusted personal GP, nurse and pharmacist who know their history and manage their health care.
Future opportunities
This study evaluated if the most significant clinical DRPs identified in patient interviews could have been identified through reviewing the health centre medication list only or through reviewing the health centre medication list and certain patient details. Clinical reports, which could have provided some extra information for us, were excluded. In the future, the use of electronic decision support tools will grow exponentially in health care, which can, together with patient involvement and patient-centred care, improve patient safety and make medication review processes more straightforward. However, to be able to make appropriate decisions based on these findings, it is essential that the information in the patient data systems is correct, up-to-date, documented in a structured way and accessible to all health care professionals who participate in patient care. Combining the use of modern information technologies, electronic decision support, data analysing tools and individual patient involvement should be considered to identify clinically significant DRPs. Furthermore, it is important to study costeffectiveness and benefits of the CMRs and patient care models from the perspective of patients, health care professionals and systems. Eventually, rational use of medicines will yield benefits to both patients and society.
Strengths and limitations of the study
The strengths are: the study was performed with real patients; it was conducted by pharmacists accredited to complete medication reviews; and it included interprofessional case conferences and evaluation of the significance of the DRPs. The limitations are: the inclusion criteria were strictly restricted to a selected patient group in one town for the research purposes, which may decrease the generalisability of the results. Since the patients in this project were ≥75-year-old outpatients and voluntary participants, these findings can be generalised only to aged home-dwelling patients. However, since we assume that the participating patients might have an interest in their health and medications, there could be even more DRPs among the nonparticipants.
Conclusion and future studies
Patient involvement is essential in identifying the most significant clinical DRPs in CMRs. Indeed, poor therapy control, nonoptimal drug use, intentional or unintentional nonadherence might otherwise be missed. Along with identifying DRPs, CMR should be taken as an opportunity to support individual health-related patient empowerment. Future research should focus on analysing procedures that strengthen patient involvement in their own care and partnership with the health care professionals. Furthermore, future research should evaluate the combination of use of electronic tools and patient interviewing techniques in finding and solving significant DRPs.
